1. Home
  2. SNGX

as of 02-13-2026 3:43pm EST

$1.10
+$0.04
+3.77%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Founded: 1987 Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 14.4M IPO Year: 1987
Target Price: $6.00 AVG Volume (30 days): 181.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.39 EPS Growth: N/A
52 Week Low/High: $1.02 - $6.23 Next Earning Date: 03-20-2026
Revenue: N/A Revenue Growth: -85.78%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: -9758227.0 FCF Growth: N/A

AI-Powered SNGX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 73.55%
73.55%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Soligenix Inc. News

SNGX Breaking Stock News: Dive into SNGX Ticker-Specific Updates for Smart Investing

All SNGX News

Share on Social Networks: